基于非糖基化位点抗体的总NT-proBNP免疫检测对心衰的诊断价值
研究纳入183例心衰和200例非心衰患者,比较靶向NT-proBNP糖基化区域与非糖基化区域的两种免疫法诊断准确性;总NT-proBNP与Ser44非糖基化亚型的ROC-AUC相似,非心衰组非糖基化/总NT-proBNP比值中位数较低,提示总NT-proBNP可能对无症状个体更敏感。
要点
- 总NT-proBNP与常规NT-proBNP诊断心衰的ROC-AUC相似
- 非心衰患者非糖基化NT-proBNP占总NT-proBNP比例更低
- 总NT-proBNP或对无/既往心衰症状者更敏感
核心结论
- 总NT-proBNP对心衰诊断的临床价值与Ser44非糖基化NT-proBNP亚型相似。
- 非心衰患者非糖基化NT-proBNP占总NT-proBNP的百分比中位数较心衰组低1.5-1.6倍,提示总NT-proBNP可能对无当前或既往心衰症状的个体更敏感。
研究设计与样本
- 纳入183例心衰和200例非心衰患者,由两名对NT-proBNP结果设盲的独立心脏科医生诊断。
- 血浆样本分未处理与糖苷酶混合处理,分别用Elecsys proBNP II(靶向糖基化区域)和SuperFlex NT-proBNP(靶向无O-糖基化区域)检测。
- 通过ROC曲线比较两种检测的诊断准确性。
主要发现
- proBNP II检测未处理样本的ROC-AUC为0.943(95%CI 0.922-0.964),糖苷酶处理样本为0.935(95%CI 0.913-0.958)。
- SuperFlex NT-proBNP检测未处理样本的ROC-AUC为0.930(95%CI 0.907-0.954)。
- 非心衰组非糖基化NT-proBNP占总NT-proBNP的百分比中位数较心衰组低1.5-1.6倍。
临床怎么用
- 总NT-proBNP检测可用于心衰诊断,诊断准确性与常规NT-proBNP检测相似。
- 对无当前或既往心衰症状的个体,总NT-proBNP可能更具敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The N-terminal fragment of pro-B-type natriuretic peptide (NT-proBNP) is a widely used heart failure (HF) biomarker. Commercial NT-proBNP immunoassays detect only a subfraction of endogenous NT-proBNP, as the antibodies target a region of NT-proBNP that could be glycosylated at Ser44. The diagnostic utility of immunoassays measuring total NT-proBNP remains unclear. METHODS: NT-proBNP was measured in 183 HF and 200 non-HF patients diagnosed by two independent cardiologists blinded to NT-proBNP results. Plasma samples either non-treated or treated with a mixture of glycosidases were analyzed by the Elecsys proBNP II assay (Roche Diagnostics, based on antibodies targeting a glycosylated region of NT-proBNP) and the SuperFlex NT-proBNP assay (PerkinElmer, based on antibodies targeting regions of NT-proBNP that are free of O-glycans). The diagnostic accuracy of the two assays was analyzed by comparison of ROC curves. RESULTS: The ROC-AUC for the proBNP II assay was 0.943 (95% CI 0.922-0.964) for NT-proBNP measured in untreated samples and 0.935 (0.913-0.958) for NT-proBNP measured in glycosidase-treated samples. The SuperFlex NT-proBNP assay in untreated samples gave a ROC-AUC of 0.930 (95% CI 0.907-0.954). The median percentage of non-glycosylated NT-proBNP to total NT-proBNP was 1.5-1.6-fold lower in the non-HF group compared to that in the HF group. CONCLUSIONS: The clinical value of total NT-proBNP for HF diagnosis was similar to the subfraction of NT-proBNP that was non-glycosylated at Ser44. The lower percentage of non-glycosylated NT-proBNP to total NT-proBNP in non-HF patients suggests that total NT-proBNP might be more sensitive in individuals without current or prior symptoms of HF.
引用
- Li L, Semenov AG, Feygina EE, et al. Diagnostic utility of total NT-proBNP testing by immunoassay based on antibodies targeting glycosylation-free regions of NT-proBNP. Clin Chem Lab Med. 2022. PMID: 36457141. doi:10.1515/cclm-2022-1194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。